コンパウンド・クシェン・インジェクションは,多発性骨髄腫の進行をTOP1標的のDNA損傷とエンドプラズマ網膜のストレスの調整によって抑制する.
PubMedで要約を見る
まとめ
この要約は機械生成です。コンパウンド・クシェン・インジェクション (CKI) はトポイソメラーゼIを標的としてDNA損傷とERストレスを誘発し,多発性骨髄腫細胞を殺害します. CKIはプロテアソーム阻害剤の有効性を高め,この不治の癌に対する潜在的補助療法を提供します.
科学分野
- 腫瘍学
- 薬理学について
- 分子生物学
背景
- 多発性骨髄腫 (MM) は不治の血細胞悪性腫瘍で,再発率が高く,治療耐性が低い.
- 伝統的な中国薬である複合クシェン注射 (CKI) は抗腫瘍的可能性を示しているが,MMにおけるそのメカニズムはよく理解されていない.
研究 の 目的
- CKIのアンチMMメカニズム,特にDNAダメージ応答 (DDR) の誘導とエンドプラズマ網膜 (ER) のストレスを調査する.
- MM治療におけるCKIとプロテアソーム阻害剤 (PI) の相乗効果を評価する.
主な方法
- MM細胞系,患者由来細胞,異種移植モデルにおけるCKI有効性の評価
- ネットワーク薬理学,トランスクリプトミックプロファイリング,分子ドッキング,CETSA,SPR,およびウェスタンブロットをメカニズム研究に使用した.
- SynergyFinder V3 を使用して CKI-PI のシネージーを評価した.
主要な成果
- CKIはインビトロとインビボでMMの増殖を抑制し,アポトーシスとG0/ G1細胞サイクル停止を引き起こした.
- CKIはトポイソメラーゼI (TOP1) を標的とし,DDRを誘発し,PERK/ATF4に依存するERストレス経路を活性化させ,TP53変異細胞でも細胞毒性を引き起こす.
- CKIは,DNA損傷とERストレスを増加させ,腫瘍負担を軽減し,重要な骨髄抑制なしの異種移植モデルで生存期間を延長することでPIの有効性を高めました.
結論
- CKIは,TOP1を標的とし,DDRとERのストレスを誘発し,PIと連携します.
- CKIは多発性骨髄腫治療における化学感受性補助剤としての可能性を示しています.
関連する概念動画
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...

